A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Pfizer
SillaJen, Inc.
Merck Sharp & Dohme LLC
Amgen
Generic Devices Consulting, Inc.
Leaf Vertical Inc.
Hoffmann-La Roche
Amgen
Pfizer
Novartis